Bio-Rad Q3 Revenues Grow 5 Percent

Nov 02, 2017

|

This article has been updated from a previous version to include comments from Bio-Rad's earnings call.

NEW YORK (GenomeWeb) – Bio-Rad said after the close of the market Thursday that its third quarter revenues increased 5 percent year over year.

For the three months ended Sept. 30, the Hercules, California-based life science research and clinical diagnostics firm tallied sales of $535.0 million compared to $508.7 million in the year-ago period, beating analysts' average estimate of $508 million. On a currency-neutral basis, net sales grew 3 percent in the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

More to Go Around

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Call for Ban

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

To Worry or Not?

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

This Week in PLOS

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.

Featured White Papers

Discovering Neuronal Cell Types

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Main menu